Charles River Laboratories International, Inc. $CRL Shares Newly Acquired by Mirae Asset Global Investments Co. Ltd.

Mirae Asset Global Investments Co. Ltd. acquired a new position in Charles River Laboratories International, Inc. (NYSE:CRL) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 25,082 shares of the medical research company’s stock, valued at approximately $7,399,000. Mirae Asset Global Investments Co. Ltd. owned about 0.05% of Charles River Laboratories International at the end of the most recent reporting period.

Several other large investors have also modified their holdings of the business. Vise Technologies Inc. lifted its holdings in shares of Charles River Laboratories International by 58.9% in the 3rd quarter. Vise Technologies Inc. now owns 3,831 shares of the medical research company’s stock worth $1,130,000 after buying an additional 1,420 shares during the period. Avestar Capital LLC purchased a new position in shares of Charles River Laboratories International during the third quarter valued at $361,000. Soltis Investment Advisors LLC bought a new stake in shares of Charles River Laboratories International in the third quarter valued at about $245,000. Choreo LLC raised its holdings in shares of Charles River Laboratories International by 2.8% in the third quarter. Choreo LLC now owns 2,165 shares of the medical research company’s stock valued at $639,000 after acquiring an additional 59 shares in the last quarter. Finally, Hanseatic Management Services Inc. purchased a new stake in Charles River Laboratories International in the third quarter worth about $588,000. Hedge funds and other institutional investors own 98.91% of the company’s stock.

Charles River Laboratories International Stock Performance

CRL stock opened at $326.62 on Thursday. The firm has a market cap of $15.59 billion, a price-to-earnings ratio of -67.34, a PEG ratio of 3.29 and a beta of 1.36. The firm has a 50-day simple moving average of $304.55 and a two-hundred day simple moving average of $224.12. Charles River Laboratories International, Inc. has a one year low of $146.20 and a one year high of $379.63. The company has a debt-to-equity ratio of 0.92, a quick ratio of 1.04 and a current ratio of 1.35.

Charles River Laboratories International (NYSE:CRL) last issued its quarterly earnings data on Wednesday, November 4th. The medical research company reported $3.09 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.97 by $0.12. The firm had revenue of $982.73 million for the quarter, compared to the consensus estimate of $960.36 million. Charles River Laboratories International had a negative net margin of 5.96% and a positive return on equity of 15.75%. The company’s quarterly revenue was down 2.2% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $2.43 EPS. On average, equities analysts forecast that Charles River Laboratories International, Inc. will post 11.38 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

CRL has been the topic of several recent research reports. JPMorgan Chase & Co. upgraded shares of Charles River Laboratories International from a “neutral” rating to an “overweight” rating and increased their target price for the stock from $180.00 to $310.00 in a report on Thursday, August 6th. Weiss Ratings restated a “sell (d-)” rating on shares of Charles River Laboratories International in a report on Monday, September 28th. Barclays boosted their price target on shares of Charles River Laboratories International from $300.00 to $330.00 and gave the company an “overweight” rating in a report on Friday, September 25th. Evercore set a $330.00 price target on shares of Charles River Laboratories International in a research report on Friday, September 25th. Finally, Zacks Research downgraded shares of Charles River Laboratories International from a “strong-buy” rating to a “hold” rating in a research note on Monday. One research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Charles River Laboratories International has a consensus rating of “Moderate Buy” and a consensus target price of $302.33.

Trending Headlines about Charles River Laboratories International

Here are the key news stories impacting Charles River Laboratories International this week:

• Positive Sentiment: Third-quarter adjusted earnings were $3.09 per share, above estimates of about $2.97, and revenue of $982.7 million beat expectations of roughly $960.4 million. Organic growth and margin expansion supported results, and the company lifted its 2026 outlook. Charles River Q3 Earnings & Revenues Top Estimates, Stock Rises
• Negative Sentiment: Despite beating estimates, revenue was down 2.2% from the same quarter last year, a possible concern for investors weighing the strong quarterly beat. Charles River Laboratories Announces Third-Quarter 2026 Results
• Negative Sentiment: Zacks Research lowered its rating on CRL from “strong-buy” to “hold,” which may have added pressure. The available reports note that shares fell despite the earnings beat and raised outlook, but do not give a definitive explanation for the market reaction. Zacks Research rating information

Insider Activity

In other news, EVP Shannon Parisotto sold 3,714 shares of the company’s stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $279.66, for a total transaction of $1,038,657.24. Following the transaction, the executive vice president directly owned 4,807 shares of the company’s stock, valued at approximately $1,344,325.62. This represents a 43.59% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Birgit Girshick sold 6,500 shares of the stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $279.90, for a total value of $1,819,350.00. Following the sale, the chief executive officer owned 36,013 shares of the company’s stock, valued at approximately $10,080,038.70. This represents a 15.29% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 102,299 shares of company stock valued at $31,050,863 over the last three months. Company insiders own 1.30% of the company’s stock.

About Charles River Laboratories International

Charles River Laboratories International, Inc is a contract research and laboratory services company that supports pharmaceutical, biotechnology, medical device and academic research organizations. The company provides products and services used throughout the drug-development process, from early discovery and research through preclinical testing and manufacturing support.

Its offerings include research models, laboratory animal management, discovery and safety assessment services, toxicology testing, bioanalysis, and support for biologic, cell and gene therapy programs.